2023
Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA and viable virus contamination of hospital emergency department surfaces and association with patient coronavirus disease 2019 (COVID-19) status and aerosol-generating procedures
Roberts S, Barbell E, Barber D, Dahlberg S, Heimer R, Jubanyik K, Parwani V, Pettigrew M, Tanner J, Ulrich A, Wade M, Wyllie A, Yolda-Carr D, Martinello R, Tanner W. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) RNA and viable virus contamination of hospital emergency department surfaces and association with patient coronavirus disease 2019 (COVID-19) status and aerosol-generating procedures. Infection Control And Hospital Epidemiology 2023, 45: 244-246. PMID: 37767709, PMCID: PMC10877528, DOI: 10.1017/ice.2023.183.Peer-Reviewed Original Research
2022
Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection
Viera A, Grau L, Fisher J, Farnum S, Tetrault J, Scott G, Heimer R. Development and pilot-testing of a hepatitis C reinfection prevention intervention for patients in treatment for hepatitis C infection. Drug And Alcohol Dependence Reports 2022, 3: 100038. PMID: 36845980, PMCID: PMC9948939, DOI: 10.1016/j.dadr.2022.100038.Peer-Reviewed Original Research
2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatmentPhysician and patient prediction of adherence to antiretroviral therapy in HIV positive people in Saint-Petersburg, Russia
Vetrova M, Aleksandrova O, Paschenko A, Toropov S, Rassokhin V, Abyshev R, Levina O, Niccolai L, Heimer R. Physician and patient prediction of adherence to antiretroviral therapy in HIV positive people in Saint-Petersburg, Russia. AIDS Care 2020, 33: 473-477. PMID: 32148065, DOI: 10.1080/09540121.2020.1738005.Peer-Reviewed Original ResearchConceptsAntiretroviral therapyHIV-positive peopleART initiationPositive peopleHIV viral suppressionPatient predictionsAccuracy of providerReview of pharmacyART retentionHIV physiciansViral suppressionPhysicians' predictionsTreatment outcomesART outcomesPatientsAdherenceLaboratory dataTherapyLongitudinal analysisOutcomesProvidersInitiationPhysiciansCare
2016
Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia
Ustinov A, Suvorova A, Belyakov A, Makhamatova A, Levina O, Krupitsky E, Lioznov D, Niccolai L, Heimer R. Psychiatric Distress, Drug Use, and HIV Viral Load Suppression in Russia. AIDS And Behavior 2016, 20: 1603-1608. PMID: 26809193, PMCID: PMC4945434, DOI: 10.1007/s10461-016-1297-x.Peer-Reviewed Original Research
2012
Speaking the truth: an analysis of gender differences in serostatus disclosure practices among HIV-infected patients in St Petersburg, Russia
Davidson A, Zaller N, Dukhovlinova E, Toussova O, Feller E, Heimer R, Kozlov A. Speaking the truth: an analysis of gender differences in serostatus disclosure practices among HIV-infected patients in St Petersburg, Russia. International Journal Of STD & AIDS 2012, 23: 685-688. PMID: 23104740, DOI: 10.1258/ijsa.2012.011463.Peer-Reviewed Original ResearchConceptsInjection drug useHIV treatmentDrug useRussian HIV epidemicCross-sectional studyHIV-positive serostatusHeterosexual spreadHIV diseaseSecondary preventionAIDS CenterAIDS clinicMean ageSexual transmissionHIV epidemicSerostatus disclosureFemale genderImportant target groupMarried statusInfection routeSexual partnersHIVPatientsImportant contact pointsMedical communityMode of acquisition
2001
Development and Application of a Genotypic AZT Resistance Assay
Kyriakides T, Heimer R. Development and Application of a Genotypic AZT Resistance Assay. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211-220. DOI: 10.1097/00126334-200111010-00002.Peer-Reviewed Original ResearchViral loadCD4 countAZT resistanceResistance indexResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentResistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityReaction assaysCountAssaysFurther supportIndexAntiretroviralsHIVDevelopment and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther support
1998
Reactivity of Human Sera to Different Strains of Granulocytic Ehrlichiae in Immunodiagnostic Assays
Magnarelli L, IJdo J, Dumler J, Heimer R, Fikrig E. Reactivity of Human Sera to Different Strains of Granulocytic Ehrlichiae in Immunodiagnostic Assays. The Journal Of Infectious Diseases 1998, 178: 1835-1838. PMID: 9815246, DOI: 10.1086/314516.Peer-Reviewed Original ResearchConceptsNCH-1 strainIndirect IFAHuman granulocytic ehrlichiosis (HGE) agentHuman granulocytic ehrlichiosisWestern blot analysisInfected neutrophilsPromyelocytic leukemia cellsHuman promyelocytic leukemia cellsAntibody detectionGranulocytic ehrlichiosisEhrlichia equiDifferent strainsHuman isolatesLeukemia cellsSerumImmunodiagnostic assaysBlot analysisGranulocytic ehrlichiaeIFA analysisHuman serumIFAEhrlichiaeAssaysSeropositivityPatientsDetection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection
Rich J, Dickinson B, Carney J, Fisher A, Heimer R. Detection of HIV-1 nucleic acid and HIV-1 antibodies in needles and syringes used for non-intravenous injection. AIDS 1998, 12: 2345-2350. PMID: 9863878, DOI: 10.1097/00002030-199817000-00017.Peer-Reviewed Original Research